GlassScriptPhysician profile
Fateh Hraky
NPI 1013933563
$4,518.26
in general payments reported to CMS, 2019-2025
33 companies · $613 in 2025
The $613 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $435 · 2021: $516 · 2022: $926 · 2023: $624 · 2024: $845 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.08 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $663.42 | 2021-2025 | |
| Abbvie INC. | $651.78 | 2019-2023 | |
| Astellas Pharma US INC | $633.17 | 2020-2025 | Veozah, Myrbetriq |
| Sage Therapeutics, LLC | $258.60 | 2022-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $226.43 | 2023-2025 | Myfembree, Gemtesa |
| Therapeuticsmd, INC. | $199.56 | 2019-2022 | |
| Organon LLC | $185.88 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $182.37 | 2019-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Scynexis, INC. | $140.88 | 2022 | |
| Aspira Women'S Health INC | $135.65 | 2019-2022 | |
| Myovant Sciences INC. | $130.39 | 2021-2022 | |
| Millicent US INC | $116.90 | 2019-2024 | Intrarosa, Femring |
| Pfizer INC. | $115.03 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $113.48 | 2019-2021 | |
| Shield Therapeutics INC | $100.31 | 2023-2024 | Accrufer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $97.89 | 2019-2020 | |
| Avion Pharmaceuticals | $61.48 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $56.96 | 2019-2022 | |
| Smith+Nephew, INC. | $55.54 | 2019 | |
| Meditrina | $53.65 | 2024-2025 | |
| Exact Sciences Corporation | $53.10 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $48.21 | 2019 | |
| Hologic Sales and Service, LLC | $41.84 | 2019-2024 | Aptima |
| Medicem INC. | $40.47 | 2020-2021 | |
| Agile Therapeutics, INC. | $32.86 | 2021 | |
| Dexcom, INC. | $25.79 | 2025 | Dexcom G6 Transmitter |
| Roche Diagnostics Corporation | $19.76 | 2019 | |
| Daiichi Sankyo INC. | $15.48 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.40 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $12.91 | 2022 | |
| Lupin INC. | $11.87 | 2019 | |
| Duchesnay USA Incorporated | $11.71 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fateh Hraky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.